Comparison of therapeutic lipid target achievements among high-risk patients in Oman

Angiology. 2014 May;65(5):430-5. doi: 10.1177/0003319713482572. Epub 2013 Apr 5.

Abstract

We compared therapeutic lipid target achievements among patients with diabetes or coronary heart disease (CHD) in Oman. A retrospective chart review of 94 patients was conducted at an outpatient clinic in Sultan Qaboos University Hospital, Muscat, Oman. The variables included low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apo B). The overall mean age of the cohort was 59 ± 12 years, 54% were male, 66% were diabetic, 48% hypertensive, 45% had CHD, 94% were on simvastatin, 4% were on fenofibrate, and 2% were on both simvastatin and fenofibrate. Lipid goal attainments of calculated LDL-C (<2.6 mmol/L), apo B (<0.9 g/L), and non-HDL-C (<3.36 mmol/L) were reached in 52%, 39%, and 53% of the patients, respectively. A significant proportion of high-risk patients treated with lipid-lowering agents reach LDL-C but not the apo B treatment targets, suggesting that the use of apo B target values should also be considered.

Keywords: Oman; apolipoprotein B; coronary heart disease; diabetes mellitus; low-density lipoprotein cholesterol.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Apolipoproteins / blood
  • Biomarkers / blood
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Coronary Disease / epidemiology
  • Diabetes Mellitus / epidemiology
  • Drug Therapy, Combination
  • Dyslipidemias / blood
  • Dyslipidemias / diagnosis
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / epidemiology
  • Female
  • Fenofibrate / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypolipidemic Agents / therapeutic use*
  • Lipids / blood*
  • Male
  • Middle Aged
  • Oman / epidemiology
  • Practice Guidelines as Topic
  • Retrospective Studies
  • Simvastatin / therapeutic use
  • Treatment Outcome

Substances

  • Apolipoproteins
  • Biomarkers
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Lipids
  • Simvastatin
  • Fenofibrate